3 Penny Stocks to Watch Now, 3/11/26

Agape ATP ATPC +7.94% ▲ , Longeveron LGVN -8.71% ▼ , and MiNK Therapeutics INKT -20.43% ▼ are the 3 Penny Stocks to watch on March 11, based on TipRanks’ Penny Stock Screener tool. These stocks are usually priced at $5 or below and typically belong to companies with a market capitalization under $300 million.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

The Penny Stock Screener allows investors to identify stocks by applying a variety of filters, including Sector, Price Target Upside, Smart Score, Analyst Consensus, Dollar Volume, and Price Change.

We leveraged the tool to identify the top three penny stocks with the highest Dollar Volume as of market close on March 10. Dollar Volume refers to the total value of shares traded in a day, calculated by multiplying the number of shares traded by the stock’s price.

Agape ATP ATPC +7.94% ▲ – Malaysia-based Agape ATP focuses on health, wellness, and energy‑saving solutions. On March 10, ATPC had a Dollar Volume of $230.18 million, while its stock price rocketed by 87%.

Agape ATP’s unit, ATPC Green Energy, partnered with Citadel Investment to collaborate on oil and gas deals. This involves identifying, structuring, and facilitating cross-border energy trades using their networks and expertise. ATPC introduces buyers and opportunities, while Citadel provides competitive pricing and supply chains.

Longeveron LGVN -8.71% ▼ – Longeveron is a clinical-stage biotechnology company based in Miami, Florida, focused on developing cellular therapies for aging-related and life-threatening conditions. Yesterday, LGVN had a Dollar Volume of $222.36 million, accompanied by a share price surge of 68.3%.

Longeveron secured up to $30 million in gross proceeds via private placement from investors like Coastlands Capital and Janus Henderson JHG -1.18% ▼ . Net proceeds from the initial closing will fund operations into Q4 2026, extending past the anticipated Q3 2026 topline data readout for ELPIS II, while investors also receive 50% interest in any future proceeds from a potential FDA Rare Pediatric Disease Priority Review Voucher tied to the laromestrocel HLHS program.

MiNK Therapeutics INKT -20.43% ▼ – MiNK Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. On Tuesday, INKT had a Dollar Volume of $213.69 million, while its stock price gained 29.3%.

MiNK Therapeutics announced a collaboration with the C-Further pediatric oncology consortium to develop a Preferentially Expressed Antigen in Melanoma (PRAME)-targeted TCR-engineered invariant natural killer T (iNKT) cell therapy for pediatric cancers like sarcomas, acute myeloid leukemia, and medulloblastoma. The company will create precise tumor-targeting treatments that also trigger broader immune responses in the tumor microenvironment. MiNK receives $1.1 million in funding to support this development.

Disclaimer & DisclosureReport an Issue